Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy

被引:53
作者
Winter, Yaroslav [1 ]
Spottke, Annika E. [2 ]
Stamelou, Maria [1 ]
Cabanel, Nicole [1 ]
Eggert, Karla [1 ]
Hoeglinger, Guenter U. [1 ]
Sixel-Doering, Friederike [3 ]
Herting, Birgit [4 ]
Klockgether, Thomas [2 ]
Reichmann, Heinz [4 ]
Oertel, Wolfgang H. [1 ]
Dodel, Richard [1 ]
机构
[1] Univ Marburg, Dept Neurol, DE-35039 Marburg, Germany
[2] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[3] Paracelsus Elena Hosp, Ctr Parkinsonism & Movement Disorders, Kassel, Germany
[4] Tech Univ Dresden, Dept Neurol, D-8027 Dresden, Germany
关键词
Atypical parkinsonian disorders; Progressive supranuclear palsy; Multiple system atrophy; Health-related quality of life; PARKINSONS-DISEASE; DIAGNOSIS; DEPRESSION; COSTS;
D O I
10.1159/000325829
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), known as atypical parkinsonian syndromes (APS), are neurodegenerative disorders with severe disability and decreased life expectancy. Little is known about the health-related quality of life (HrQoL) and its determinants in patients with those disorders. The objective of our cross-sectional study was to evaluate the HrQoL in patients with APS and to identify the determinants of HrQoL. Methods: A total of 101 consecutive patients with MSA (n = 54) and PSP (n = 47) were recruited in four German neurological centers. Disease severity was assessed using the Hoehn and Yahr stages and the Unified MSA Rating Scale. The HrQoL was evaluated using the EuroQol instrument (EQ-5D and EQ-VAS). Independent determinants of HrQoL were identified in multiple regression analyses. Results: The mean EQ-VAS score was 52% lower than that reported for the general population (36.9 +/- 18.3 vs. 77.4 +/- 19.0). Of the study participants, 63% reported severe problems in at least one dimension of the EQ-5D. Cerebellar dysfunction was associated with a more considerable reduction of HrQoL. Independent determinants of reduced HrQoL were female gender, <12 years of education, disease severity, a decreased number of persons in the household and depression. Conclusions: The HrQoL in MSA and PSP is considerably reduced. While therapeutic options in the treatment of motor symptoms remain restricted, greater attention should be paid to the treatment of depression, which was identified among independent determinants of HrQoL. Independent determinants of HrQoL should be considered when developing healthcare programs aimed at improving the HrQoL in APS. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:438 / 446
页数:9
相关论文
共 50 条
  • [31] Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy
    Tomse, Petra
    Rebec, Eva
    Studen, Andrej
    Perovnik, Matej
    Rus, Tomaz
    Lezaic, Luka
    Tang, Chris C.
    Eidelberg, David
    Trost, Maja
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2022, 98 : 131 - 138
  • [32] The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy
    Serrao, Mariano
    Di Fabio, Roberto
    Bartolo, Michelangelo
    Perrotta, Armando
    Tassorelli, Cristina
    Coppola, Gianluca
    Davassi, Chiara
    Padua, Luca
    Sandrini, Giorgio
    Pierelli, Francesco
    CLINICAL NEUROPHYSIOLOGY, 2011, 122 (09) : 1812 - 1815
  • [33] Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy
    Wenning, G. K.
    Colosimo, C.
    REVUE NEUROLOGIQUE, 2010, 166 (10) : 829 - 833
  • [34] A Short Progressive Supranuclear Palsy Quality of Life Scale
    Jensen, Ida
    Stiel, Stephanie
    Bebermeier, Sarah
    Schrag, Anette
    Greten, Stephan
    Doll-Lee, Johanna
    Wegner, Florian
    Ye, Lan
    Heine, Johanne
    Krey, Lea
    Hoellerhage, Matthias
    Suess, Patrick
    Winkler, Juergen
    Berg, Daniela
    Paschen, Steffen
    Toenges, Lars
    Gruber, Doreen
    Gandor, Florin
    Jost, Wolfgang H.
    Kuehn, Andrea A.
    Claus, Inga
    Warnecke, Tobias
    Pedrosa, David J.
    Eggers, Carsten
    Trenkwalder, Claudia
    Classen, Joseph
    Schwarz, Johannes
    Poetter-Nerger, Monika
    Kassubek, Jan
    Schnitzler, Alfons
    Hoeglinger, Guenter U.
    Klietz, Martin
    MOVEMENT DISORDERS, 2024, 39 (09) : 1602 - 1609
  • [35] Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
    Lee, Sang-Wook
    Koh, Seong-Beom
    JOURNAL OF MOVEMENT DISORDERS, 2012, 5 (02) : 42 - 47
  • [36] Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges
    Respondek, Gesine
    Levin, Johannes
    Hoeglinger, Guenter U.
    CURRENT OPINION IN NEUROLOGY, 2018, 31 (04) : 448 - 454
  • [37] Clinical speech impairment in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy
    Sachin, S.
    Shukla, G.
    Goyal, V.
    Singh, S.
    Aggarwal, Vijay
    Gureshkumar
    Behari, M.
    NEUROLOGY INDIA, 2008, 56 (02) : 122 - 126
  • [38] Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy
    Bessemer, Robin
    Iansavichene, Alla
    Jenkins, Mary E.
    Finger, Elizabeth
    Gofton, Teneille E.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 448
  • [39] Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy
    D. Testa
    D. Monza
    M. Ferrarini
    P. Soliveri
    F. Girotti
    G. Filippini
    Neurological Sciences, 2001, 22 : 247 - 251
  • [40] Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
    Mori, Akio
    Ishikawa, Kei-Ichi
    Saiki, Shinji
    Hatano, Taku
    Oji, Yutaka
    Okuzumi, Ayami
    Fujimaki, Motoki
    Koinuma, Takahiro
    Ueno, Shin-Ichi
    Imamichi, Yoko
    Hattori, Nobutaka
    PLOS ONE, 2019, 14 (09):